Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.62 |
| ▸ | GHSR | Q92847 | 3/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711230 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL1711453 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL31254405 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL1711233 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL30579779 | 0.99 | GNPAT (0.61) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL16970314 | 0.95 | GNPAT (0.60) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL16970311 | 0.95 | GNPAT (0.60) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL31181219 | 0.95 | GNPAT (0.57) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL30497010 | 0.95 | GNPAT (0.57) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL29531757 | 0.95 | GHSR (0.56) | GNPATGHSRERAP2LNPEPCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | claimed |
| CN-118909043-A | Bicyclic peptide ligands specific for EPHA2 | 拜斯科技术开发有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-118598945-A | Bicyclic peptide ligands specific for EphA2 | 拜斯科技术开发有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-111741771-B | Bicyclic peptide ligands specific for EPHA2 | 拜斯科技术开发有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-111787955-B | Bicyclic peptide ligands specific for EphA2 | 拜斯科技术开发有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-116419929-B | Engineered EGFR antibodies with reduced affinity, drug conjugates and uses thereof | 百力司康生物医药(杭州)有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| CN-110088086-B | Disubstituted maleimide-based linker for antibody-drug coupling, preparation method and application thereof | 迈威(上海)生物科技股份有限公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | claimed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | claimed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | claimed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | GNPAT 1927/4885GHSR 2481/4885ERAP2 3834/4885 |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | GNPAT 1352/4885GHSR 264/4885ERAP2 106/4885 |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | F3, F13B, TFPI | GNPAT 1327/4885GHSR 3632/4885ERAP2 1294/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | GNPAT 3326/4885GHSR 777/4885ERAP2 1536/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | GNPAT 243/4885GHSR 1973/4885ERAP2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.